Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves Outcomes in Pretreated Patients with Metastatic Cancer By Ogkologos - October 14, 2025 361 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROME study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Tyrosine Kinase Inhibitor Prolongs Progression-Free Survival in Rare Neuroendocrine Tumours [ESMO... September 20, 2021 Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should... February 8, 2024 Καρκίνος Δέρματος January 20, 2019 FDA Approves Injectable Nivolumab, an Alternative to IV Infusion February 19, 2025 Load more HOT NEWS Encouraging Early Results Seen with Novel MEDI1191 in Advanced Tumours New on NCI’s Websites for April 2024 EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of... FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection
